Public Health · 7 h ago
New EU supply chain aims to resolve Visudyne shortage in 2027
The European Medicines Agency reports that a new EU supply chain has been established for Visudyne (verteporfin). The long-standing shortage of the eye medicine is expected to be resolved in 2027.
- A new EU supply chain has been established for verteporfin.
- The shortage is expected to be resolved in 2027.
- Country-specific availability and supply volumes are not provided.
A new European Union supply chain has been established for Visudyne (verteporfin), according to a European Medicines Agency notice dated 4 September 2026. The agency describes the development as an important step towards resolving a long-standing shortage of the eye medicine, with resolution expected in 2027. The supplied excerpt highlights coordination between the European Commission, EU Member States, the MSSG and the SPOC Working Party in addressing medicine shortages. It does not provide supply volumes, country-specific availability or details of the new supply chain. The projected resolution should therefore not be interpreted as confirmation that routine availability has already been restored.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
European Medicines Agency: New EU supply chain to end Visudyne shortage ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.